Doggett Statement on H.R. 3: The Lower Drug Costs Now Act
***Press Release***
FOR IMMEDIATE RELEASE Sept. 19, 2019 | Contact: Kate Stotesbery 202-225-4865 |
Doggett Statement on H.R. 3: The Lower Drug Costs Now Act
Washington, D.C. — Today, U.S. Representative Lloyd Doggett (D-TX), Chair of the House Ways and Means Health Subcommittee, released the following statement in regards to today's release of H.R. 3: The Lower Drug Costs Now Act:
"This legislation is stronger because of progressive involvement, but more is required, including addressing negotiation scope, sky-high launch prices, and price-spike protection for all patients. My goal remains delivering the most relief possible for the most patients and preventing Big Pharma from dodging responsibility for widespread price-gouging of the sick and dying. Competitive licensing strikes at the heart of government-approved monopoly power. While continuing to believe that enabling such generic competition represents the best way to achieve lasting reform, it is not the only way. Since this new bill was promoted as the way to sway President Trump and a reluctant Republican Senate, I await their embrace. Since effective legislation will not only save consumers but also taxpayers, some of the substantial savings should be used to improve Medicare, including the dental, hearing, and vision care proposal that I have advanced."
###
Follow Congressman Doggett